We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-5.19%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.1B
AUM Growth
-$269M
Cap. Flow
-$108M
Cap. Flow %
-9.78%
Top 10 Hldgs %
61.03%
Holding
57
New
53
Increased
–
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$260M
2
NFH
New Frontier Health Corporation Ordinary Shares
NFH
+$130M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$68.1M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$54M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$45.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 87.06%
2 Financials 10.69%
3 Materials 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
51
DBV Technologies
DBVT
$852M
$1.06M 0.1%
+27,000
New +$2.42M
NBRV
52
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$980K 0.09%
+6,817
New +$2.09M
DTIL icon
53
Precision BioSciences
DTIL
$207M
$846K 0.08%
+4,675
New +$1.22M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Vivo Capital held 57 positions worth $1.1B, down 20% from $1.37B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Vivo Capital withdrew a net $108M in Q1 2020, closing 4 positions.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Ascendis Pharma A/S worth $226M.

  • Vivo Capital's largest Q1 2020 buy was Ascendis Pharma A/S: 2,003,147 shares worth $226M.
  • Vivo Capital's ten largest holdings make up 61% of its $1.1B portfolio in Q1 2020.
  • Vivo Capital opened 53 new positions and closed 4 in Q1 2020.
  • Vivo Capital's portfolio value fell 20% quarter-over-quarter to $1.1B.

Based on Vivo Capital's 13F filing for Q1 2020, filed 15 May 2020.